1. In vivo daptomycin efficacy against experimental vancomycin-resistant Enterococcus faecium endocarditis
- Author
-
Sophie Reissier, Idir Ghout, Laurent Massias, Azzam Saleh-Mghir, Anne-Claude Crémieux, Clara Sinel, Vincent Cattoir, François Guérin, Infection et inflammation chronique ( 2IC ), Université de Versailles Saint-Quentin-en-Yvelines ( UVSQ ) -Institut National de la Santé et de la Recherche Médicale ( INSERM ), CHU Caen, ARN régulateurs bactériens et médecine ( BRM ), Université de Rennes 1 ( UR1 ), Université de Rennes ( UNIV-RENNES ) -Université de Rennes ( UNIV-RENNES ) -Institut National de la Santé et de la Recherche Médicale ( INSERM ) -Structure Fédérative de Recherche en Biologie et Santé de Rennes ( Biosit : Biologie - Santé - Innovation Technologique ), AP-HP - Hôpital Bichat - Claude Bernard [Paris], Hôpital Ambroise Paré, Unité de Recherche Risques Microbiens ( U2RM ), Université de Caen Normandie ( UNICAEN ), Normandie Université ( NU ) -Normandie Université ( NU ), Ministere de l'Enseignement Superieur et de la Recherche [EA4655], Infection et inflammation (2I), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Versailles Saint-Quentin-en-Yvelines (UVSQ), Normandie Université (NU)-Tumorothèque de Caen Basse-Normandie (TCBN), ARN régulateurs bactériens et médecine (BRM), Université de Rennes 1 (UR1), Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Structure Fédérative de Recherche en Biologie et Santé de Rennes ( Biosit : Biologie - Santé - Innovation Technologique ), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Hôpital Ambroise Paré [AP-HP], Unité de Recherche Risques Microbiens (U2RM), Université de Caen Normandie (UNICAEN), Normandie Université (NU)-Normandie Université (NU), Université de Versailles Saint-Quentin-en-Yvelines (UVSQ)-Institut National de la Santé et de la Recherche Médicale (INSERM), and Université de Rennes (UR)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Structure Fédérative de Recherche en Biologie et Santé de Rennes ( Biosit : Biologie - Santé - Innovation Technologique )
- Subjects
0301 basic medicine ,Microbiology (medical) ,medicine.medical_specialty ,030106 microbiology ,Enterococcus faecium ,Gastroenterology ,03 medical and health sciences ,0302 clinical medicine ,Daptomycin ,In vivo ,Mutant strain ,[ SDV.MP ] Life Sciences [q-bio]/Microbiology and Parasitology ,Internal medicine ,medicine ,High doses ,Endocarditis ,Animals ,Pharmacology (medical) ,030212 general & internal medicine ,Gram-Positive Bacterial Infections ,Vancomycin resistant Enterococcus faecium ,Pharmacology ,biology ,business.industry ,Vancomycin Resistance ,Endocarditis, Bacterial ,medicine.disease ,biology.organism_classification ,Bacterial Load ,3. Good health ,Anti-Bacterial Agents ,Disease Models, Animal ,Infectious Diseases ,Treatment Outcome ,[SDV.MP]Life Sciences [q-bio]/Microbiology and Parasitology ,Infective endocarditis ,Female ,Rabbits ,business ,medicine.drug - Abstract
International audience; Objectives - Daptomycin has become a first-line therapeutic option for vancomycin-resistant Enterococcus faecium infective endocarditis (IE). Although high doses (≥8 mg/kg) are often recommended, optimal doses, particularly for strains with MICs close to the susceptibility breakpoint (4 mg/L), are still debated.Methods - Daptomycin efficacy at doses equivalent to 8 mg/kg daptomycin (DAP8) and 12 mg/kg daptomycin (DAP12) in humans was evaluated in a rabbit model of aortic valve IE induced by 108 cfu of E. faecium reference strain Aus0004 (daptomycin MIC = 2 mg/L) or its in vitro mutant strain Mut4 (daptomycin MIC = 4 mg/L). Treatment began 48 h post-inoculation and lasted 5 days.Results - With Aus0004, the median log10 cfu/g of vegetations was significantly lower after DAP8 and DAP12 versus controls [6.05 (n = 12) and 2.15 (n = 10) versus 9.14 (n = 11), respectively; P Conclusions - DAP12 was the most successful strategy against IE due to a WT E. faecium strain (daptomycin MIC = 2 mg/L). To treat IE strains with MIC = 4 mg/L, DAP8 or DAP12 monotherapy was poorly effective with the risk of resistant mutant emergence. Reassessment of the daptomycin susceptibility breakpoint for enterococci seems necessary.
- Published
- 2018
- Full Text
- View/download PDF